Derval O'Carroll
Responsabile della Conformità presso INFLARX N.V.
Patrimonio netto: - $ in data 30/06/2024
Posizioni attive di Derval O'Carroll
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| INFLARX N.V. | Responsabile della Conformità | 01/01/2022 | - |
| Consigliere Generale | 01/01/2022 | - |
Storia della carriera di Derval O'Carroll
Precedenti posizioni note di Derval O'Carroll
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| TRAVERE THERAPEUTICS, INC. | Consigliere Generale | 01/12/2015 | 01/12/2017 |
| AMRYT PHARMA PLC | Consigliere Generale | - | - |
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Consigliere Generale | 24/01/2018 | - |
Formazione di Derval O'Carroll
| University College Dublin | Graduate Degree |
Statistiche
Distribuzione geografica
| Regno Unito | 3 |
| Irlanda | 2 |
| Stati Uniti | 2 |
Posizioni
| General Counsel | 4 |
| Graduate Degree | 1 |
| Masters Business Admin | 1 |
Settori
| Health Technology | 5 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| TRAVERE THERAPEUTICS, INC. | Health Technology |
| INFLARX N.V. | Health Technology |
| Aziende private | 2 |
|---|---|
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
Amryt Pharma Plc
 Amryt Pharma Plc Pharmaceuticals: MajorHealth Technology Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded in August 2015 and is headquartered in Dublin, Ireland. | Health Technology |
- Borsa valori
- Insiders
- Derval O'Carroll
- Esperienza
